Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Четыре группы неинфекционных заболеваний в поликлиническом звене здравоохранения: анализ данных медицинских информационных систем - Научно-практический журнал Cardioсоматика Том 16, №1 (2025)
Четыре группы неинфекционных заболеваний в поликлиническом звене здравоохранения: анализ данных медицинских информационных систем
Какорина Е.П., Самородская И.В., Ларина В.Н., Ларин В.Г. Четыре группы неинфекционных заболеваний в поликлиническом звене здравоохранения: анализ данных медицинских информационных систем // CardioСоматика. 2025. Т. 16. № 1. С. 53–61. DOI: 10.17816/CS635911 EDN: AHIJCR
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Обоснование. Всемирная организация здравоохранения для разработки программ профилактики и снижения смертности использует понятие четырёх основных групп неинфекционных заболеваний (НИЗ), ассоциируемых с высоким уровнем смертности.
Цель. Оценка возможностей и проблем использования медицинских информационных систем (МИС) для учёта четырёх групп НИЗ в амбулаторном звене здравоохранения.
Материалы и методы. Персонифицированные обезличенные данные на 86 266 умерших, которые обращались в амбулаторно-поликлинические государственные учреждения Московской области по любому поводу за год до смерти. В анализ включены 4 группы НИЗ: злокачественные новообразования, болезни системы кровообращения (БСК, I00-I99), хроническая обструктивная болезнь лёгких, сахарный диабет. Лабораторные и инструментальные исследования, медицинские вмешательства в данном исследовании не выполнялись и не анализировались. Статистический анализ выполнен с использованием программ SPSS 26.0, Microsoft Excel.
Результаты. Сочетание любых двух из анализируемых четырёх групп заболеваний имелись у 17,5%, трёх — у 2,2%, четырёх — у 0,07% пациентов; изолированно одно из четырёх групп зарегистрировано у 48,1%, БСК — у 59,8% (артериальная гипертензия — 38,6%, ишемическая болезнь сердца — 20,1%); злокачественные новообразования — у 15,9%, сахарный диабет — у 12,2%, хроническая обструктивная болезнь лёгких — у 2,1% пациентов. За год до смерти у 67,9% пациентов зарегистрированы заболевания из четырёх групп НИЗ, однако только у половины из них причиной смерти были перечисленные нозологии. Пациенты с указанными НИЗ чаще обращались за медицинской помощью, чем пациенты, не имеющие заболевания (р <0,001). Максимальное количество обращений (38,5±16,2) зарегистрировано у пациентов (средний возраст 70,6±7,7), имевших все четыре группы НИЗ. В среднем на одного пациента зарегистрировано 4,9±4,3 заболевания (кода МКБ-10), что косвенно свидетельствует о мультиморбидности.
Заключение. Каждый третий амбулаторный пациент за год до смерти не имел ни одного заболевания из четырёх анализируемых НИЗ, чаще других регистрировались БСК, что следует учитывать при создании клинических рекомендаций. МИС могут заменить регистры для решения клинических проблем, но отсутствие чётких правил внесения значимых нозологий (например, сердечная недостаточность, фибрилляция предсердий) препятствуют их использованию.
Ключевые слова: болезни системы кровообращения, хроническая обструктивная болезнь лёгких, сахарный диабет, первичное звено здравоохранения, медицинские информационные системы, амбулаторные пациенты
AIM: To evaluate the capabilities and limitations of using medical information systems to monitor the four major noncommunicable diseases groups in outpatient health care.
MATERIALS AND METHODS: Depersonalized individual-level data were collected for 86 266 deceased individuals who had sought care for any reason at public outpatient clinics in the Moscow region during the year preceding death. The analysis included four groups of noncommunicable diseases: malignant neoplasms, cardiovascular diseases (ICD-10 codes I00–I99), chronic obstructive pulmonary disease, and diabetes mellitus. Laboratory and instrumental tests, as well as medical interventions, were not performed or analyzed. Statistical analyses were performed using SPSS, version 26.0 (IBM Corp) and Microsoft Excel (Microsoft Corp).
RESULTS: A combination of any two of the four analyzed noncommunicable diseases groups was identified in 17.5% of patients; three groups in 2.2%; and all four groups in 0.07%. A single noncommunicable diseases group was recorded in 48.1% of cases. Circulatory system diseases were present in 59.8% of patients, including hypertension in 38.6% and coronary artery disease in 20.1%. Malignant neoplasms were diagnosed in 15.9%, diabetes mellitus in 12.2%, and chronic obstructive pulmonary disease in 2.1%. Within the year preceding death, 67.9% of patients had at least one diagnosis from the four major noncommunicable diseases groups; however, in only half of these cases were these diagnostic categories listed as the underlying cause of death. Patients with any of the four noncommunicable diseases had significantly more frequent outpatient visits compared with those without such conditions (p <0.001). The highest number of visits (38.5±16.2) was observed in patients (mean age, 70.6±7.7 years) with diagnoses from all four noncommunicable diseases groups. On average, 4.9±4.3 ICD-10 codes were recorded per patient, indirectly indicating the presence of multimorbidity.
CONCLUSION: One in three outpatients had no diagnoses from the four analyzed noncommunicable diseases groups in the year preceding death. Circulatory system diseases were the most frequently recorded and should be prioritized in the development of clinical guidelines. Medical information systems have the potential to serve as alternatives to disease registries in addressing clinical challenges; however, the absence of standardized protocols for recording clinically significant conditions (e.g., heart failure, atrial fibrillation) limits their practical utility.
Keywords: circulatory system diseases, chronic obstructive pulmonary disease, diabetes mellitus, primary health care, medical information systems, outpatients
Цель. Оценка возможностей и проблем использования медицинских информационных систем (МИС) для учёта четырёх групп НИЗ в амбулаторном звене здравоохранения.
Материалы и методы. Персонифицированные обезличенные данные на 86 266 умерших, которые обращались в амбулаторно-поликлинические государственные учреждения Московской области по любому поводу за год до смерти. В анализ включены 4 группы НИЗ: злокачественные новообразования, болезни системы кровообращения (БСК, I00-I99), хроническая обструктивная болезнь лёгких, сахарный диабет. Лабораторные и инструментальные исследования, медицинские вмешательства в данном исследовании не выполнялись и не анализировались. Статистический анализ выполнен с использованием программ SPSS 26.0, Microsoft Excel.
Результаты. Сочетание любых двух из анализируемых четырёх групп заболеваний имелись у 17,5%, трёх — у 2,2%, четырёх — у 0,07% пациентов; изолированно одно из четырёх групп зарегистрировано у 48,1%, БСК — у 59,8% (артериальная гипертензия — 38,6%, ишемическая болезнь сердца — 20,1%); злокачественные новообразования — у 15,9%, сахарный диабет — у 12,2%, хроническая обструктивная болезнь лёгких — у 2,1% пациентов. За год до смерти у 67,9% пациентов зарегистрированы заболевания из четырёх групп НИЗ, однако только у половины из них причиной смерти были перечисленные нозологии. Пациенты с указанными НИЗ чаще обращались за медицинской помощью, чем пациенты, не имеющие заболевания (р <0,001). Максимальное количество обращений (38,5±16,2) зарегистрировано у пациентов (средний возраст 70,6±7,7), имевших все четыре группы НИЗ. В среднем на одного пациента зарегистрировано 4,9±4,3 заболевания (кода МКБ-10), что косвенно свидетельствует о мультиморбидности.
Заключение. Каждый третий амбулаторный пациент за год до смерти не имел ни одного заболевания из четырёх анализируемых НИЗ, чаще других регистрировались БСК, что следует учитывать при создании клинических рекомендаций. МИС могут заменить регистры для решения клинических проблем, но отсутствие чётких правил внесения значимых нозологий (например, сердечная недостаточность, фибрилляция предсердий) препятствуют их использованию.
Ключевые слова: болезни системы кровообращения, хроническая обструктивная болезнь лёгких, сахарный диабет, первичное звено здравоохранения, медицинские информационные системы, амбулаторные пациенты
________________________________________________
AIM: To evaluate the capabilities and limitations of using medical information systems to monitor the four major noncommunicable diseases groups in outpatient health care.
MATERIALS AND METHODS: Depersonalized individual-level data were collected for 86 266 deceased individuals who had sought care for any reason at public outpatient clinics in the Moscow region during the year preceding death. The analysis included four groups of noncommunicable diseases: malignant neoplasms, cardiovascular diseases (ICD-10 codes I00–I99), chronic obstructive pulmonary disease, and diabetes mellitus. Laboratory and instrumental tests, as well as medical interventions, were not performed or analyzed. Statistical analyses were performed using SPSS, version 26.0 (IBM Corp) and Microsoft Excel (Microsoft Corp).
RESULTS: A combination of any two of the four analyzed noncommunicable diseases groups was identified in 17.5% of patients; three groups in 2.2%; and all four groups in 0.07%. A single noncommunicable diseases group was recorded in 48.1% of cases. Circulatory system diseases were present in 59.8% of patients, including hypertension in 38.6% and coronary artery disease in 20.1%. Malignant neoplasms were diagnosed in 15.9%, diabetes mellitus in 12.2%, and chronic obstructive pulmonary disease in 2.1%. Within the year preceding death, 67.9% of patients had at least one diagnosis from the four major noncommunicable diseases groups; however, in only half of these cases were these diagnostic categories listed as the underlying cause of death. Patients with any of the four noncommunicable diseases had significantly more frequent outpatient visits compared with those without such conditions (p <0.001). The highest number of visits (38.5±16.2) was observed in patients (mean age, 70.6±7.7 years) with diagnoses from all four noncommunicable diseases groups. On average, 4.9±4.3 ICD-10 codes were recorded per patient, indirectly indicating the presence of multimorbidity.
CONCLUSION: One in three outpatients had no diagnoses from the four analyzed noncommunicable diseases groups in the year preceding death. Circulatory system diseases were the most frequently recorded and should be prioritized in the development of clinical guidelines. Medical information systems have the potential to serve as alternatives to disease registries in addressing clinical challenges; however, the absence of standardized protocols for recording clinically significant conditions (e.g., heart failure, atrial fibrillation) limits their practical utility.
Keywords: circulatory system diseases, chronic obstructive pulmonary disease, diabetes mellitus, primary health care, medical information systems, outpatients
Полный текст
Список литературы
1. Kanev AF, Kobyakova OS, Kurakova NG, Shibalkov IP. Population ageing and national healthcare systems sustainability. A review of world practices. National Health Care. 2023;4(4):5–13. doi: 10.47093/2713-069X.2023.4.4.5-13 EDN: SNXYKK
2. World Health Organization. The top 10 causes of death. Available from: https://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death
3. Schwartz LN, Shaffer JD, Bukhman G. The origins of the 4 × 4 framework for noncommunicable disease at the World Health Organization. SSM Popul Health. 2021;13:100731. doi: 10.1016/j.ssmph.2021.100731
4. Heller O, Somerville C, Suggs LS, et al. The process of prioritization of non-communicable diseases in the global health policy arena. Health Policy Plan. 2019;34(5):370–383. doi: 10.1093/heapol/czz043 EDN: YYLIHO
5. World Health Organization. (2022). Key facts on noncommunicable diseases. Available from: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases. Accessed: 09.06.2024
6. Kontsevaya AV, Myrzamatova AO, Mukaneeva DK, et al. The economic burden of main non-communicable diseases in the Russian Federation in 2016. Russian Journal of Preventive Medicine. 2019;22(6):18–23. doi: 10.17116//profmed20192206118 EDN: BWCFVW
7. Borovkova NYu, Tokareva AS, Savitskaya NN, et al. Current status of the problem of cardiovascular diseases in the Nizhny Novgorod region: possible ways to reduce mortality. Russian Journal of Cardiology. 2022;27(5):5024. doi: 10.15829/1560-4071-2022-5024 EDN: IECBDD
8. Conrad N, Jhund PS, Sattar N, et al. Incidence of cardiovascular diseases over the past 20 years — a population-based study in 22 million individuals. European Heart Journal. 2023;44(Suppl 2):ehad655.3036. doi: 10.1093/eurheartj/ehad655.3036 EDN: RTDMYP
9. Boytsov SA, Drapkina OM, Shlyakhto EV, et al. Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation (ESSERF) study. Ten years later. Cardiovascular Therapy and Prevention. 2021;20(5):3007. doi: 10.15829/1728-8800-2021-3007 EDN: ZPGROP
10. Balanova YuA, Kontsevaya AV, Myrzamatova AO, et al. Economic Burden of Hypertension in the Russian Federation. Rational Pharmacotherapy in Cardiology. 2020;16(3):415–423. doi: 10.20996/1819-6446-2020-05-03 EDN: AGBXDV
11. GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2133–2161. doi: 10.1016/S0140-6736(24)00757-8
12. Dolgalev IV, Ivanova AYu, Shipkhineeva AYu. Hypertension as a death risk factor in men and women aged 20-59 years: a 34-year cohort prospective study. Cardiovascular Therapy and Prevention. 2023;22(8):3602. doi: 10.15829/1728-8800-2023-3602 EDN: DNFNSW
13. Zhang X, Padhi A, Wei T, et al. Community prevalence and dyad disease pattern of multimorbidity in China and India: a systematic review. BMJ Glob Health. 2022;7(9):e008880. doi: 10.1136/bmjgh-2022-008880 EDN: LGHTDE
14. Nizov AA, Suchkova EI, Dashkevich OV, Trunina TP. Cardiovascular comorbidity in the real clinical practice of an ambulatory physician. Comparative register research in the Ryazan region. Cardiovascular Therapy and Prevention. 2019;18(2):70–75. doi: 10.15829/1728-8800-2019-2-70-75 EDN: VYWUZU
15. Loukianov MM, Kontsevaya AV, Myrzamatova AO, et al. Patients with Combination of Cardiovascular Diseases and Type 2 Diabetes in RECVASA and REGION Registries: Multimorbidity, Outcomes and Potential Effect of Dapagliflozin in the Russian Clinical Practice. Rational Pharmacotherapy in Cardiology. 2020;16(1):59–68. doi: 10.20996/1819-6446-2020-02-03 EDN: VGZTLG
16. Andreenko EYu, Lukyanov MM, Yakushin SS, et al. Young ambulatory patients with cardiovascular diseases: age and gender characteristics, comorbidity, medication and outcomes (according to RECVASA register). Cardiovascular Therapy and Prevention. 2019;18(6):99–106. doi: 10.15829/1728-8800-2019-6-99-106 EDN: QDRMGD
17. Li Z, Zhang Z, Ren Y, et al. Aging and age-related diseases: from mechanisms to therapeutic strategies. Biogerontology. 2021;22(2):165–187. doi: 10.1007/s10522-021-09910-5 EDN: ARCTCB
18. Zuo X, Li X, Tang K, et al. Sarcopenia and cardiovascular diseases: A systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2023;14(3):1183–1198. doi: 10.1002/jcsm.13221 EDN: EGNQTH
19. Kaluvu L, Asogwa OA, Marzà-Florensa A, et al. Multimorbidity of communicable and non-communicable diseases in low- and middle-income countries: A systematic review. J Multimorb Comorb. 2022;12:26335565221112593. doi: 10.1177/26335565221112593 EDN: GMZXZQ
20. Sabayan B, Goudarzi R, Ji Y, et al. Intracranial Atherosclerosis Disease Associated With Cognitive Impairment and Dementia: Systematic Review and Meta-Analysis. J Am Heart Assoc. 2023;12(22):e032506. doi: 10.1161/JAHA.123.032506 EDN: HDMZNY
21. Wang M, Muraki I, Liu K, et al. Diabetes and Mortality From Respiratory Diseases: The Japan Collaborative Cohort Study. J Epidemiol. 2020;30(10):457–463. doi: 10.2188/jea.JE20190091 EDN: KAAYUZ
22. Tolpygina SN, Zagrebelny AV, Chernysheva MI, et al. Long-term survival of patients with cerebrovascular accident, depending on sex and age: data from the REGION-M registry. Cardiovascular Therapy and Prevention. 2023;22(7):3596. doi: 10.15829/1728-8800-2023-3596 EDN: EVMQFD
2. World Health Organization. The top 10 causes of death. Available from: https://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death
3. Schwartz LN, Shaffer JD, Bukhman G. The origins of the 4 × 4 framework for noncommunicable disease at the World Health Organization. SSM Popul Health. 2021;13:100731. doi: 10.1016/j.ssmph.2021.100731
4. Heller O, Somerville C, Suggs LS, et al. The process of prioritization of non-communicable diseases in the global health policy arena. Health Policy Plan. 2019;34(5):370–383. doi: 10.1093/heapol/czz043 EDN: YYLIHO
5. World Health Organization. (2022). Key facts on noncommunicable diseases. Available from: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases. Accessed: 09.06.2024
6. Kontsevaya AV, Myrzamatova AO, Mukaneeva DK, et al. The economic burden of main non-communicable diseases in the Russian Federation in 2016. Russian Journal of Preventive Medicine. 2019;22(6):18–23. doi: 10.17116//profmed20192206118 EDN: BWCFVW
7. Borovkova NYu, Tokareva AS, Savitskaya NN, et al. Current status of the problem of cardiovascular diseases in the Nizhny Novgorod region: possible ways to reduce mortality. Russian Journal of Cardiology. 2022;27(5):5024. doi: 10.15829/1560-4071-2022-5024 EDN: IECBDD
8. Conrad N, Jhund PS, Sattar N, et al. Incidence of cardiovascular diseases over the past 20 years — a population-based study in 22 million individuals. European Heart Journal. 2023;44(Suppl 2):ehad655.3036. doi: 10.1093/eurheartj/ehad655.3036 EDN: RTDMYP
9. Boytsov SA, Drapkina OM, Shlyakhto EV, et al. Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation (ESSERF) study. Ten years later. Cardiovascular Therapy and Prevention. 2021;20(5):3007. doi: 10.15829/1728-8800-2021-3007 EDN: ZPGROP
10. Balanova YuA, Kontsevaya AV, Myrzamatova AO, et al. Economic Burden of Hypertension in the Russian Federation. Rational Pharmacotherapy in Cardiology. 2020;16(3):415–423. doi: 10.20996/1819-6446-2020-05-03 EDN: AGBXDV
11. GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2133–2161. doi: 10.1016/S0140-6736(24)00757-8
12. Dolgalev IV, Ivanova AYu, Shipkhineeva AYu. Hypertension as a death risk factor in men and women aged 20-59 years: a 34-year cohort prospective study. Cardiovascular Therapy and Prevention. 2023;22(8):3602. doi: 10.15829/1728-8800-2023-3602 EDN: DNFNSW
13. Zhang X, Padhi A, Wei T, et al. Community prevalence and dyad disease pattern of multimorbidity in China and India: a systematic review. BMJ Glob Health. 2022;7(9):e008880. doi: 10.1136/bmjgh-2022-008880 EDN: LGHTDE
14. Nizov AA, Suchkova EI, Dashkevich OV, Trunina TP. Cardiovascular comorbidity in the real clinical practice of an ambulatory physician. Comparative register research in the Ryazan region. Cardiovascular Therapy and Prevention. 2019;18(2):70–75. doi: 10.15829/1728-8800-2019-2-70-75 EDN: VYWUZU
15. Loukianov MM, Kontsevaya AV, Myrzamatova AO, et al. Patients with Combination of Cardiovascular Diseases and Type 2 Diabetes in RECVASA and REGION Registries: Multimorbidity, Outcomes and Potential Effect of Dapagliflozin in the Russian Clinical Practice. Rational Pharmacotherapy in Cardiology. 2020;16(1):59–68. doi: 10.20996/1819-6446-2020-02-03 EDN: VGZTLG
16. Andreenko EYu, Lukyanov MM, Yakushin SS, et al. Young ambulatory patients with cardiovascular diseases: age and gender characteristics, comorbidity, medication and outcomes (according to RECVASA register). Cardiovascular Therapy and Prevention. 2019;18(6):99–106. doi: 10.15829/1728-8800-2019-6-99-106 EDN: QDRMGD
17. Li Z, Zhang Z, Ren Y, et al. Aging and age-related diseases: from mechanisms to therapeutic strategies. Biogerontology. 2021;22(2):165–187. doi: 10.1007/s10522-021-09910-5 EDN: ARCTCB
18. Zuo X, Li X, Tang K, et al. Sarcopenia and cardiovascular diseases: A systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2023;14(3):1183–1198. doi: 10.1002/jcsm.13221 EDN: EGNQTH
19. Kaluvu L, Asogwa OA, Marzà-Florensa A, et al. Multimorbidity of communicable and non-communicable diseases in low- and middle-income countries: A systematic review. J Multimorb Comorb. 2022;12:26335565221112593. doi: 10.1177/26335565221112593 EDN: GMZXZQ
20. Sabayan B, Goudarzi R, Ji Y, et al. Intracranial Atherosclerosis Disease Associated With Cognitive Impairment and Dementia: Systematic Review and Meta-Analysis. J Am Heart Assoc. 2023;12(22):e032506. doi: 10.1161/JAHA.123.032506 EDN: HDMZNY
21. Wang M, Muraki I, Liu K, et al. Diabetes and Mortality From Respiratory Diseases: The Japan Collaborative Cohort Study. J Epidemiol. 2020;30(10):457–463. doi: 10.2188/jea.JE20190091 EDN: KAAYUZ
22. Tolpygina SN, Zagrebelny AV, Chernysheva MI, et al. Long-term survival of patients with cerebrovascular accident, depending on sex and age: data from the REGION-M registry. Cardiovascular Therapy and Prevention. 2023;22(7):3596. doi: 10.15829/1728-8800-2023-3596 EDN: EVMQFD
2. World Health Organization. The top 10 causes of death. Available from: https://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death
3. Schwartz LN, Shaffer JD, Bukhman G. The origins of the 4 × 4 framework for noncommunicable disease at the World Health Organization. SSM Popul Health. 2021;13:100731. doi: 10.1016/j.ssmph.2021.100731
4. Heller O, Somerville C, Suggs LS, et al. The process of prioritization of non-communicable diseases in the global health policy arena. Health Policy Plan. 2019;34(5):370–383. doi: 10.1093/heapol/czz043 EDN: YYLIHO
5. World Health Organization. (2022). Key facts on noncommunicable diseases. Available from: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases. Accessed: 09.06.2024
6. Kontsevaya AV, Myrzamatova AO, Mukaneeva DK, et al. The economic burden of main non-communicable diseases in the Russian Federation in 2016. Russian Journal of Preventive Medicine. 2019;22(6):18–23. doi: 10.17116//profmed20192206118 EDN: BWCFVW
7. Borovkova NYu, Tokareva AS, Savitskaya NN, et al. Current status of the problem of cardiovascular diseases in the Nizhny Novgorod region: possible ways to reduce mortality. Russian Journal of Cardiology. 2022;27(5):5024. doi: 10.15829/1560-4071-2022-5024 EDN: IECBDD
8. Conrad N, Jhund PS, Sattar N, et al. Incidence of cardiovascular diseases over the past 20 years — a population-based study in 22 million individuals. European Heart Journal. 2023;44(Suppl 2):ehad655.3036. doi: 10.1093/eurheartj/ehad655.3036 EDN: RTDMYP
9. Boytsov SA, Drapkina OM, Shlyakhto EV, et al. Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation (ESSERF) study. Ten years later. Cardiovascular Therapy and Prevention. 2021;20(5):3007. doi: 10.15829/1728-8800-2021-3007 EDN: ZPGROP
10. Balanova YuA, Kontsevaya AV, Myrzamatova AO, et al. Economic Burden of Hypertension in the Russian Federation. Rational Pharmacotherapy in Cardiology. 2020;16(3):415–423. doi: 10.20996/1819-6446-2020-05-03 EDN: AGBXDV
11. GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2133–2161. doi: 10.1016/S0140-6736(24)00757-8
12. Dolgalev IV, Ivanova AYu, Shipkhineeva AYu. Hypertension as a death risk factor in men and women aged 20-59 years: a 34-year cohort prospective study. Cardiovascular Therapy and Prevention. 2023;22(8):3602. doi: 10.15829/1728-8800-2023-3602 EDN: DNFNSW
13. Zhang X, Padhi A, Wei T, et al. Community prevalence and dyad disease pattern of multimorbidity in China and India: a systematic review. BMJ Glob Health. 2022;7(9):e008880. doi: 10.1136/bmjgh-2022-008880 EDN: LGHTDE
14. Nizov AA, Suchkova EI, Dashkevich OV, Trunina TP. Cardiovascular comorbidity in the real clinical practice of an ambulatory physician. Comparative register research in the Ryazan region. Cardiovascular Therapy and Prevention. 2019;18(2):70–75. doi: 10.15829/1728-8800-2019-2-70-75 EDN: VYWUZU
15. Loukianov MM, Kontsevaya AV, Myrzamatova AO, et al. Patients with Combination of Cardiovascular Diseases and Type 2 Diabetes in RECVASA and REGION Registries: Multimorbidity, Outcomes and Potential Effect of Dapagliflozin in the Russian Clinical Practice. Rational Pharmacotherapy in Cardiology. 2020;16(1):59–68. doi: 10.20996/1819-6446-2020-02-03 EDN: VGZTLG
16. Andreenko EYu, Lukyanov MM, Yakushin SS, et al. Young ambulatory patients with cardiovascular diseases: age and gender characteristics, comorbidity, medication and outcomes (according to RECVASA register). Cardiovascular Therapy and Prevention. 2019;18(6):99–106. doi: 10.15829/1728-8800-2019-6-99-106 EDN: QDRMGD
17. Li Z, Zhang Z, Ren Y, et al. Aging and age-related diseases: from mechanisms to therapeutic strategies. Biogerontology. 2021;22(2):165–187. doi: 10.1007/s10522-021-09910-5 EDN: ARCTCB
18. Zuo X, Li X, Tang K, et al. Sarcopenia and cardiovascular diseases: A systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2023;14(3):1183–1198. doi: 10.1002/jcsm.13221 EDN: EGNQTH
19. Kaluvu L, Asogwa OA, Marzà-Florensa A, et al. Multimorbidity of communicable and non-communicable diseases in low- and middle-income countries: A systematic review. J Multimorb Comorb. 2022;12:26335565221112593. doi: 10.1177/26335565221112593 EDN: GMZXZQ
20. Sabayan B, Goudarzi R, Ji Y, et al. Intracranial Atherosclerosis Disease Associated With Cognitive Impairment and Dementia: Systematic Review and Meta-Analysis. J Am Heart Assoc. 2023;12(22):e032506. doi: 10.1161/JAHA.123.032506 EDN: HDMZNY
21. Wang M, Muraki I, Liu K, et al. Diabetes and Mortality From Respiratory Diseases: The Japan Collaborative Cohort Study. J Epidemiol. 2020;30(10):457–463. doi: 10.2188/jea.JE20190091 EDN: KAAYUZ
22. Tolpygina SN, Zagrebelny AV, Chernysheva MI, et al. Long-term survival of patients with cerebrovascular accident, depending on sex and age: data from the REGION-M registry. Cardiovascular Therapy and Prevention. 2023;22(7):3596. doi: 10.15829/1728-8800-2023-3596 EDN: EVMQFD
________________________________________________
2. World Health Organization. The top 10 causes of death. Available from: https://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death
3. Schwartz LN, Shaffer JD, Bukhman G. The origins of the 4 × 4 framework for noncommunicable disease at the World Health Organization. SSM Popul Health. 2021;13:100731. doi: 10.1016/j.ssmph.2021.100731
4. Heller O, Somerville C, Suggs LS, et al. The process of prioritization of non-communicable diseases in the global health policy arena. Health Policy Plan. 2019;34(5):370–383. doi: 10.1093/heapol/czz043 EDN: YYLIHO
5. World Health Organization. (2022). Key facts on noncommunicable diseases. Available from: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases. Accessed: 09.06.2024
6. Kontsevaya AV, Myrzamatova AO, Mukaneeva DK, et al. The economic burden of main non-communicable diseases in the Russian Federation in 2016. Russian Journal of Preventive Medicine. 2019;22(6):18–23. doi: 10.17116//profmed20192206118 EDN: BWCFVW
7. Borovkova NYu, Tokareva AS, Savitskaya NN, et al. Current status of the problem of cardiovascular diseases in the Nizhny Novgorod region: possible ways to reduce mortality. Russian Journal of Cardiology. 2022;27(5):5024. doi: 10.15829/1560-4071-2022-5024 EDN: IECBDD
8. Conrad N, Jhund PS, Sattar N, et al. Incidence of cardiovascular diseases over the past 20 years — a population-based study in 22 million individuals. European Heart Journal. 2023;44(Suppl 2):ehad655.3036. doi: 10.1093/eurheartj/ehad655.3036 EDN: RTDMYP
9. Boytsov SA, Drapkina OM, Shlyakhto EV, et al. Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation (ESSERF) study. Ten years later. Cardiovascular Therapy and Prevention. 2021;20(5):3007. doi: 10.15829/1728-8800-2021-3007 EDN: ZPGROP
10. Balanova YuA, Kontsevaya AV, Myrzamatova AO, et al. Economic Burden of Hypertension in the Russian Federation. Rational Pharmacotherapy in Cardiology. 2020;16(3):415–423. doi: 10.20996/1819-6446-2020-05-03 EDN: AGBXDV
11. GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2133–2161. doi: 10.1016/S0140-6736(24)00757-8
12. Dolgalev IV, Ivanova AYu, Shipkhineeva AYu. Hypertension as a death risk factor in men and women aged 20-59 years: a 34-year cohort prospective study. Cardiovascular Therapy and Prevention. 2023;22(8):3602. doi: 10.15829/1728-8800-2023-3602 EDN: DNFNSW
13. Zhang X, Padhi A, Wei T, et al. Community prevalence and dyad disease pattern of multimorbidity in China and India: a systematic review. BMJ Glob Health. 2022;7(9):e008880. doi: 10.1136/bmjgh-2022-008880 EDN: LGHTDE
14. Nizov AA, Suchkova EI, Dashkevich OV, Trunina TP. Cardiovascular comorbidity in the real clinical practice of an ambulatory physician. Comparative register research in the Ryazan region. Cardiovascular Therapy and Prevention. 2019;18(2):70–75. doi: 10.15829/1728-8800-2019-2-70-75 EDN: VYWUZU
15. Loukianov MM, Kontsevaya AV, Myrzamatova AO, et al. Patients with Combination of Cardiovascular Diseases and Type 2 Diabetes in RECVASA and REGION Registries: Multimorbidity, Outcomes and Potential Effect of Dapagliflozin in the Russian Clinical Practice. Rational Pharmacotherapy in Cardiology. 2020;16(1):59–68. doi: 10.20996/1819-6446-2020-02-03 EDN: VGZTLG
16. Andreenko EYu, Lukyanov MM, Yakushin SS, et al. Young ambulatory patients with cardiovascular diseases: age and gender characteristics, comorbidity, medication and outcomes (according to RECVASA register). Cardiovascular Therapy and Prevention. 2019;18(6):99–106. doi: 10.15829/1728-8800-2019-6-99-106 EDN: QDRMGD
17. Li Z, Zhang Z, Ren Y, et al. Aging and age-related diseases: from mechanisms to therapeutic strategies. Biogerontology. 2021;22(2):165–187. doi: 10.1007/s10522-021-09910-5 EDN: ARCTCB
18. Zuo X, Li X, Tang K, et al. Sarcopenia and cardiovascular diseases: A systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2023;14(3):1183–1198. doi: 10.1002/jcsm.13221 EDN: EGNQTH
19. Kaluvu L, Asogwa OA, Marzà-Florensa A, et al. Multimorbidity of communicable and non-communicable diseases in low- and middle-income countries: A systematic review. J Multimorb Comorb. 2022;12:26335565221112593. doi: 10.1177/26335565221112593 EDN: GMZXZQ
20. Sabayan B, Goudarzi R, Ji Y, et al. Intracranial Atherosclerosis Disease Associated With Cognitive Impairment and Dementia: Systematic Review and Meta-Analysis. J Am Heart Assoc. 2023;12(22):e032506. doi: 10.1161/JAHA.123.032506 EDN: HDMZNY
21. Wang M, Muraki I, Liu K, et al. Diabetes and Mortality From Respiratory Diseases: The Japan Collaborative Cohort Study. J Epidemiol. 2020;30(10):457–463. doi: 10.2188/jea.JE20190091 EDN: KAAYUZ
22. Tolpygina SN, Zagrebelny AV, Chernysheva MI, et al. Long-term survival of patients with cerebrovascular accident, depending on sex and age: data from the REGION-M registry. Cardiovascular Therapy and Prevention. 2023;22(7):3596. doi: 10.15829/1728-8800-2023-3596 EDN: EVMQFD
Авторы
Е.П. Какорина2, И.В. Самородская2, В.Н. Ларина*1, В.Г. Ларин1
1Российский национальный исследовательский медицинский университет им. Н.И. Пирогова, Москва, Россия;
2Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского, Москва, Россия
*larinav@mail.ru
1Pirogov Russian National Research Medical University, Moscow, Russia;
2Vladimirsky Moscow Regional Research Clinical Institute, Moscow, Russia
*larinav@mail.ru
1Российский национальный исследовательский медицинский университет им. Н.И. Пирогова, Москва, Россия;
2Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского, Москва, Россия
*larinav@mail.ru
________________________________________________
1Pirogov Russian National Research Medical University, Moscow, Russia;
2Vladimirsky Moscow Regional Research Clinical Institute, Moscow, Russia
*larinav@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.
